At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 6,586 enrolled

Drug / intervention

Erlotinibdrug

Likely dose

Erlotinib 150 milligramsfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00949910

NCT00949910Phase 4Completed

Compare CT.gov

An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer

Hoffmann-La Roche·interventional·Posted Jul 31, 2009·Updated Oct 5, 2016

In Brief

A Phase 4 clinical trial evaluating Erlotinib for Non-Small Cell Lung Cancer. Completed, enrolled 6,586 participants across 543 sites in 51 countries.

Detailed Summary

This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either. Efficacy and safety will be monitored throughout the study.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-Small Cell Lung Cancer

CountriesAlbania, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Ecuador, Egypt, Estonia, Finland, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Panama, Peru, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, South Korea, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Uruguay, Venezuela

Collaborators--

Timeline

Phase 4CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartNov 2004

Primary CompletionApr 2009

First PostedJul 2009

TodayJul 2026

First PostedJul 31, 2009

Enrollment StartNov 1, 2004

Primary CompletionApr 1, 2009

TodayJul 2, 2026

Enrollment to primary: 4.4 yearsPosted 16.9 years ago

Interventions

Erlotinibdrug

Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.